Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Nanogel That Delivers One-two Punch to Cancer Heads to Clinical Trial

By Drug Discovery Trends Editor | April 6, 2016

A cutaway illustration of the nanogel developed by professor Tarek Fahmy. The small particle can carry multiple drug agents to a specific target, such as the site of a tumor. (Illustration by Nicolle Rager Fuller, NSF)An immunotherapy drug delivery system created at Yale that can carry multiple drugs inside a tiny particle is heading toward its first phase of clinical trials for a possible new treatment for cancer.
 
The delivery system, a nanogel developed in the lab of associate professor Tarek Fahmy, can be used for multiple combinations of drugs for many different cancers and some immune disorders. The platform is designed to deliver multiple drugs with different chemical properties. A single particle can carry hundreds of drug molecules that concentrate in the tumor, increasing the efficacy of the drug combination while decreasing its toxicity.
 
Fahmy describes the delivery system as a kind of “rational” therapy, in that it fuses established biological and clinical findings to the emerging field of nanotechnology.
 
“It creates a new solution that could potentially deal a significant blow to cancer and even autoimmune disease in future applications,” said Fahmy, who teaches biomedical engineering and immunobiology.
 
The first use of this delivery system will be a drug known as IMM-01. A multi-pronged treatment for metastatic cancer, it contains two agents: Interleukin-2 (IL-2) and an inhibitor of tissue growth factor (TGF beta). IL-2 amplifies the body’s immune system, while the TGF-beta inhibitor dampens the cancer cells’ ability to hide from the immune system. Because their size and makeup differ greatly, the two agents would normally be incompatible. Fahmy, however, developed a novel biodegradable gel that can contain both drugs and then release them in the tumor.
 
TVM Life Science Ventures VII is providing funding to Modulate Therapeutics Inc. to develop the drug to clinical proof of concept. Modulate secured the rights to IMM-01 from Yale and the Yale start-up company Immunova L.L.C., which was co-founded by Fahmy, Johns Hopkins University professor of oncology Ephraim Fuchs, and entrepreneur Bernard Friedman.
 
Friedman noted that the complexity of disease biology often hinders treatments. “Successful therapies must strike multiple targets,” he said. “The technology developed by Dr. Fahmy provides an elegant solution.”
 
“It’s about leveraging the biology of the system, not fighting it,” added Brian Horsburgh, CEO of Immunova and Modulate. “You want to wake up the immune system and harness that.”
 
Yale’s Office of Cooperative Research (OCR) helped launch Immunova in 2012 and develop Fahmy’s drug delivery technology. Fahmy is a member of the Yale Cancer Center.
 
“It’s great to see this technology moving forward to the clinic, and we’re hopeful that this will be the first of many life-saving drugs to use this technology,” said Dr. John Puziss, director of technology licensing in OCR.
 
Source: Yale University

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50